From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
5-methyl-6-[(3,4,5-trimethoxyphenyl) aminomethyl] quinazoline-2,4-diamine
Pharmacokinetic data
Bioavailability VD: 20-30 Liters
Metabolism Oxidative O-demethylation, followed by conjugation with glucuronide or sulfate
Biological half-life 11 to 12 hours
CAS Number 52128-35-5
ATC code P01AX07 (WHO)
PubChem CID 5583
DrugBank APRD00268
Chemical data
Formula C19H23N5O3
Molar mass 369.418 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Trimetrexate is a quinazoline derivative. It is a dihydrofolate reductase inhibitor.[1]


It has been used with leucovorin in treating pneumocystis pneumonia.[2]

It has been investigated for use in treating leiomyosarcoma.[3] It is a methotrexate (MTX) analog that is active against transport-deficient MTX-resistant tumor cells that overcome the acquired and natural resistance to methotrexate. Other uses include skin lymphoma. [4]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. Wong BK, Woolf TF, Chang T, Whitfield LR (1990). "Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog". Drug Metab. Dispos. 18 (6): 980–6. PMID 1981548. 
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  4. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol. 2002 Jun 15;20(12):2876-80.